Cisplatin and Vindesine Combination Chemotherapy for Advanced Carcinoma of the Lung: A Randomized Trial Investigating Two Dosage Schedules

摘要: Eighty-five patients with advanced squamous carcinoma or adenocarcinoma of the lung were randomly assigned to receive vindesine either high dose (120 mg/m2 body surface area) low (60 mg/m2) cisplatin. All had measurable disease and not previously received chemotherapy. The response rate was similar both treatments (43% complete partial remission rate), but cisplatin regimen superior in median duration (12 versus 5.5 months; p = 0.05) survival for responding (21.7 10 0.02). Myelosuppression generally a treatment problem; peripheral neuropathy moderate azotemia major dose-limiting toxicities. With improved rates over those reported conventional regimens, this combination new agents supports approach drug investigation cancer importance incorporation active into initial chemotherapy regimens.